Doxorubicin pharmacokinetics: Macromolecule binding, metabolism, and excretion in the context of a physiologic model.
about
Comparison of conventional chemotherapy, stealth liposomes and temperature-sensitive liposomes in a mathematical modelQuantitative Analysis of the Enhanced Permeation and Retention (EPR) EffectThe distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumorsStability and in vivo evaluation of pullulan acetate as a drug nanocarrier.Temperature sensitive liposomes combined with thermal ablation: Effects of duration and timing of heating in mathematical models and in vivoA Mendelian locus on chromosome 16 determines susceptibility to doxorubicin nephropathy in the mouse.State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicinesPhase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer.Mathematical spatio-temporal model of drug delivery from low temperature sensitive liposomes during radiofrequency tumour ablationPhase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphomaIncorporation of ABCB1-mediated transport into a physiologically-based pharmacokinetic model of docetaxel in mice.The preliminary evaluation on cholesterol-modified pullulan as a drug nanocarrier.Thermal and pH Sensitive Multifunctional Polymer Nanoparticles for Cancer Imaging and TherapyA physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding.Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of miceA Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to HumansDoxorubicin Blocks Cardiomyocyte Autophagic Flux by Inhibiting Lysosome Acidification.Canine osteosarcoma cell lines from patients with differing serum alkaline phosphatase concentrations display no behavioural differences in vitro.Chemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells.Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans.Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues.Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines.A biologically based dose-response model for dietary iodide and the hypothalamic-pituitary-thyroid axis in the adult rat: evaluation of iodide deficiency.Development of a limited-sampling model for prediction of doxorubicin exposure in dogs.Fasting Reduces the Incidence of Delayed-Type Vomiting Associated with Doxorubicin Treatment in Dogs with Lymphoma.A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin-integration of in vitro results, Phase I and Phase II data and model application for drug-drug interaction potential analysis.Effects of Cyclophosphamide (CYP) and/or Doxorubicin (DOX) in a Murine Model of Post-Chemotherapy Cognitive Impairment.Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation.Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice.Targeted drug delivery by high intensity focused ultrasound mediated hyperthermia combined with temperature-sensitive liposomes: computational modelling and preliminary in vivovalidation.Acid-sensitive lipidated doxorubicin prodrug entrapped in nanoemulsion impairs lung tumor metastasis in a breast cancer model.Precision Medicine with Imprecise Therapy: Computational Modeling for Chemotherapy in Breast Cancer.Schedule dependent synergy of gemcitabine and doxorubicin: Improvement of in vitro efficacy and lack of in vitro-in vivo correlation.A complex micellar system co-delivering curcumin with doxorubicin against cardiotoxicity and tumor growth
P2860
Q28484470-E9C8D0A2-E94F-40D9-A6B7-4E9BF33656C4Q28547003-184660C6-3202-469D-9078-AD5E9BB43253Q33595085-296778CE-8BD2-4AF5-864C-5E695A74746FQ33605225-4E750687-17AF-4839-A967-970989D22CF3Q33788183-02A6DD93-4C1D-4920-AFFC-EF386ECDA7B5Q33851089-B8E0E51D-AD1F-4DE5-B4B6-CD84BE65A3ECQ34045119-C9694712-D35C-4213-BBC5-DAA5BAB26E9CQ34168530-F1084ADE-9056-4248-8927-A919EF81D68EQ34217254-90A798C9-75D1-4E9A-B58E-148E8D930541Q34373001-2D8EC678-C9E1-47FD-A25C-65399BCF9A48Q34937463-61F27219-DF87-420C-84BB-54CEBEA280F4Q35119645-335F7E5C-77A2-4353-851F-6DA9F3CF79ECQ35202143-5F3D9B3D-8316-488D-B98A-04AD60DA7764Q35888381-6589F3DC-4E2F-476D-8EB3-9EBE1685E78BQ36411053-27AB6412-A2D6-4B97-9D2C-66ECB82A245EQ36445112-510F2605-7D0F-4DBC-957A-624B27E7482EQ36869450-73B8E98B-3383-45CA-A0FA-81C75FB79D2AQ37045893-C52314FF-DA0A-4BCC-BF2D-79A0DAED1FB7Q37387342-A0DE31AC-87AA-4CAF-B6B9-2D54D34119F4Q37498669-869BEFF4-A0D0-42DE-A191-FB6FD262D95DQ39150971-EC09BD54-B0C4-40AA-8F76-8FB4DADE9FD8Q39225305-6653464F-38AB-429E-A028-6A40A4A57E6DQ40136525-79C29E27-31BF-4AAC-8DBD-D6E20A3BC62DQ41882636-CC2FA875-AB6F-4345-A19E-1530C210AC08Q42742139-7B80B060-0565-45F7-9E27-9495D9847A0AQ47369407-03F7851E-51C2-4713-92CE-446DDED90CE2Q47566624-6D2EB35D-2A5C-45DA-BF01-540D4909BFDAQ50036781-73A6A983-BD8D-4AA5-8243-AF4E0CF2A98AQ50061323-B9CAC1BB-F4FD-42EF-9D61-E9BDB0879BD7Q50245200-F4CDAA8B-8B28-4653-BC36-241DE4CA427AQ51827976-A6B44ECC-77E6-4C27-B913-592B0187B93FQ52576799-BB4E8A0C-5C8B-4B70-943D-BC08D7E18D01Q53465288-0D799771-E929-4F2A-B39B-24DD0B73D79EQ58790268-FE813882-3EF1-4FD5-8ACB-5496CD97332E
P2860
Doxorubicin pharmacokinetics: Macromolecule binding, metabolism, and excretion in the context of a physiologic model.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Doxorubicin pharmacokinetics: ...... ontext of a physiologic model.
@ast
Doxorubicin pharmacokinetics: ...... ontext of a physiologic model.
@en
type
label
Doxorubicin pharmacokinetics: ...... ontext of a physiologic model.
@ast
Doxorubicin pharmacokinetics: ...... ontext of a physiologic model.
@en
prefLabel
Doxorubicin pharmacokinetics: ...... ontext of a physiologic model.
@ast
Doxorubicin pharmacokinetics: ...... ontext of a physiologic model.
@en
P2093
P356
P1476
Doxorubicin pharmacokinetics: ...... ontext of a physiologic model.
@en
P2093
Daniel L Gustafson
Jeffrey C Rastatter
Michael E Long
Tina Colombo
P304
P356
10.1002/JPS.10161
P407
P577
2002-06-01T00:00:00Z